Wellthy Therapeutics
Also: Datos Health ties off $7 million in Series A funding; Wellthy Therapeutics collects $4 million in pre-Series A; Lifesprk fleshes out tech with $16.1 million.
At the 79th Annual Scientific Sessions of the American Diabetes Association in San Francisco, pharma giant Roche and India-based digital therapeutics company Wellthy Therapeutics presented real world data of improved diabetes care outcomes in a South Asian population when patients followed prescribed plan of medication and lifestyle modification in conjunction with a combination therapy of self-monitoring blood glucose device and a clinically validated digital therapeutic (DTx).